U.S. Patent Office Extends Mifamurtide Patent Term for Third Time

Summary

The United States Patent and Trademark Office has granted a third one-year interim extension to the term of U.S. Patent No. 4,971,802, which covers Mifamurtide, a cancer treatment drug.